COVID‐19 vaccine response in people with multiple sclerosis
…, N Vickaryous, V Anderson, AN Asardag… - Annals of …, 2022 - Wiley Online Library
Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2…
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2…
COVID-19 humoral and T-cell mediated vaccination responses in people with multiple sclerosis
…, F Rios, L Schalk, AN Asardag… - Multiple Sclerosis …, 2022 - pesquisa.bvsalud.org
Background: For people living with MS (pwMS) the impact of disease modifying treatments (DMT)
on vaccine efficacy has been a growing concern. Method (s) We used remote …
on vaccine efficacy has been a growing concern. Method (s) We used remote …
COVID-19 vaccine response in people with multiple sclerosis (preprint)
EC Tallantyre, N Vickaryous, V Anderson, AN Asardag… - 2021 - pesquisa.bvsalud.org
Objective: To investigate the effect of disease modifying therapies on serological response
to SARS-CoV2 vaccines in people with multiple sclerosis Methods: 473 people with multiple …
to SARS-CoV2 vaccines in people with multiple sclerosis Methods: 473 people with multiple …
Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the …
… Emma C Tallantyre, Nicola Vickaryous, Valerie Anderson, Aliye Nazli Asardag, David Baker,
Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George, Gavin …
Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George, Gavin …
[HTML][HTML] Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
EC Tallantyre, MJ Scurr, N Vickaryous… - Multiple Sclerosis and …, 2022 - Elsevier
Background People with MS treated with anti-CD20 therapies and fingolimod often have
attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the …
attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the …
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
SA Zaloum, CH Wood, P Tank… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Background: People with multiple sclerosis (pwMS) treated with certain disease-modifying
therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, …
therapies (DMTs) have attenuated IgG response following COVID-19 vaccination; however, …
